Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate

Bioavailability Clinical Trial

Official title:

Influence of a High-fat Meal on the Bioavailability of a Two Different Formulations of Risedronate

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00755872
• Other study ID #: 2007120
• Status: Completed
• Phase: Phase 1
• First received: September 18, 2008
• Last updated: October 7, 2011
• Start date: November 2007
• Est. completion date: February 2008

Study information

• Verified date: October 2011
• Source: Warner Chilcott
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a randomized, open-label, multi-center, 4-treatment, 4-period crossover study. Approximately 72 healthy, surgically sterile or postmenopausal subjects will be enrolled and have urine collected over 72 hours following administration of risedronate for all 4 treatment periods).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: February 2008
• Est. primary completion date: February 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Females 40 - 70 years at time of first dose

• BMI less than or equal to 32 kg/square meter

• Non-lactating and either surgically sterile or postmenopausal

Exclusion Criteria:

• Clinically significant uncontrolled cardiovascular, hepatic, renal, or thyroid disease

• Had a major surgical operation requiring inpatient hospitalization within 1 month prior to screening or plans to have a major surgical operation during the course of the study

• A history of cancer within the past 5 years, except for basal cell carcinoma with documentation of a 6-month remission at screening. Subjects with a more recent history of successfully treated cervical carcinoma in situ will not be excluded, provided there is documentation of a 12-month remission

• Any disease or surgery known to alter normal gastrointestinal structure or function

• A history of gastrointestinal disease (peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease, irritable bowel syndrome, or moderate to severe gastro-esophageal reflux disease that requires prescription or frequent [> 3 times/week] nonprescription medicinal intervention [eg, antacids])

• A history of gastrointestinal surgery, with the exception of appendectomy and hernia repair that did not require bowel resection (subjects who have undergone appendectomy or hernia repair within the 12 months prior to screening will be excluded from the study)

• Acute gastritis, diarrhea or constipation within the 14-day period prior to the predicted first dosing day. If screening occurs >14 days before the first dosing day, subjects will be re-evaluated for eligibility at admission. Diarrhea will be defined as the passage of liquid feces and/or a stool frequency of greater than 3 times per day. Constipation will be defined as having less than 3 bowel movements per week or as having fewer bowel movements than is usual for the subject

Exclusion at Admission:

• Any significant change from screening which in the investigator's opinion would impact safety of subject or interfere with the evaluation of the study drug.

• Had any acute illness within the past 2 weeks.

• Consumed alcohol, grapefruit or grapefruit juice, orange juice, chocolate, or caffeine within 72 hours of dosing.

• Used a bisphosphonate since screening.

• Reported exposure to any known enzyme inducer or inhibitor, transport induceror inhibitor or nonmedical enzyme-inducers such as paint solvents or pesticides since screening.

• A positive pregnancy test.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Bioavailability

Intervention

Drug:
• Risedronate
Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
• Risedronate
Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
• Risedronate
Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
• Risedronate
Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.

Locations

Country	Name	City	State
United States	Research Site	Austin	Texas
United States	Research Site	Ft Myers	Florida
United States	Research Site	Miramar	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Warner Chilcott	Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the relative bioavailability of the 35 mg DR risedronate tablet administered immediately after a high-fat meal compared to the 35 mg IR risedronate tablet administered 30 minutes prior to a high-fat meal.		4 Days	No
Secondary	Assess the relative bioavailability of a 35 mg DR risedronate tablet administered immediately after a high-fat meal compared to the same 35 mg DR risedronate tablet administered under fasted conditions.		4 Days	No